-
Major cancer drugs could become cheaper as India considers import duty waiver
11 Jul 2025 05:18 GMT
… Indian Council of Medical Research (ICMR), the Department of Pharmaceuticals, and the … is to make life-saving treatments, such as those for cancer … drugs on the list include Zolgensma, Spinraza, Evrysdi, Cerezyme, and Takhzyro. These medications …
-
India may relax import duty on 200 drugs; blockbuster cancer meds Keytruda, Enhertu on list
11 Jul 2025 04:00 GMT
… Indian Council of Medical Research (ICMR), Department of Pharmaceuticals and Directorate General … and enzyme replacement treatments—are among the most expensive drugs in the … , Spinraza, Evrysdi, Cerezyme, and Takhzyro. All these drugs are very expensive …
-
Global Cerezyme Market Forecast: Key Growth Drivers, Trends, And Opportunities From 2025 To 2034
05 Mar 2025 11:36 GMT
… medical tourism, enhancing patient mobility for specialized care
oIncrease in clinical trials … of personalized medicine, tailoring treatments to … in biotechnology, supporting drug innovation … Cerezyme market growth is Sanofi S.A. This pharmaceutical …
-
Cerezyme Global Market Report 2025: Projected Growth, Influential Trends, and Key Players
23 Jan 2025 17:58 GMT
… rise in medical tourism, increased numbers of clinical trials, and … , rising investments in biotechnology, and an uptick … Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies, … /report/cerezyme-global-market-report
The …
-
FDA cites contamination concerns in warning to Sanofi MA plant
22 Jan 2025 14:50 GMT
… (cGMP) for drug substance production.
“FDA documented that approximately … can reproduce an active pharmaceutical ingredient (API) with … from both the FDA and European Medicines Agency (EMA) … of both Fabrazyme and Cerezyme (imiglucerase for injection) …
-
ISU Abxis’ Gaucher disease drug enters Middle East-North African market
12 Dec 2024 07:07 GMT
… launch of its Gaucher disease treatment Abcertin (imiglucerase) in the Middle … Middle East 2024,” an international pharmaceutical and biotechnology exhibition, held at the … ’s Cerezyme, which ISU Abxis developed.
Tabuk is a leading pharmaceutical company …
-
Human medicines European public assessment report (EPAR): Cerezyme, imiglucerase, Date of authorisation: 17/11/1997, Revision: 32, Status: Authorised
23 May 2024 09:19 GMT
Cerezyme is used for the long-term treatment of patients with Gaucher disease … , and bone pain and breaks.
Cerezyme is used in patients who … enlarged liver or spleen.
The medicine can only be obtained with …
-
Earnings call: Fulcrum Therapeutics partners with Sanofi on FSHD drug
14 May 2024 02:22 GMT
… with the FDA and European regulators on clinical trials and … typically inherent for any biotech company undertaking the commercial … pain medications, and hydroxyurea, but all of these treatments only … programs such as Fabrazyme and Cerezyme, Myozyme. I mean, …
-
Sanofi to bring 5 of its best-selling drugs to India
01 Apr 2024 14:51 GMT
… , Allegra, Enterogermina, Combiflam Cardace and Cerezyme, among others.
Globally, the company … potential in diabetes treatments through a mix of remedial options that comprise … brands, including Frisium anti-epileptic drugs through its partnership with Cipla …
-
Neuronopathic therapies are a serious unmet need in the treatment of Gaucher disease
19 Oct 2023 12:16 GMT
… ERTs include Sanofi’s Cerezyme (imiglucerase), Takeda’s … the creation of drugs designed to cross … with fast-track FDA designation, PR001 treatment could significantly … Looking ahead, collaboration between pharmaceutical innovators, dedicated researchers, …